Products and Vaccines

• To print this page, please use the File menu or press simultaneously ctrl + p keys.
• Send this page

Sanofi-aventis has an extensive portfolio of prescription drugs, vaccines, generics and consumer healthcare products targeting a balanced mix of traditional markets and emerging countries¹.

Prescription medicines

In 2009, pharmaceutical sales increased by 3.7% to €25.823 million, of which 23.381 million for prescription medicines partly driven by the Group's major products in the diabetes, thrombosis and oncology.

Among these, Lantus® confirms its position as the leading brand of insulin on the world market with sales of €3,080 million in 2009, boosted by the success of the SoloSTAR® pen injector. Lovenox® remains the global leader of low-molecular weight heparins, growing by 8.8% with sales of €3,043 million in 2009. Despite competition from generics in Europe, Plavix® increased sales by 6.2% in 2009 to €6,782 million (world sales²). In oncology, Taxotere® grew by 6.1% in 2009 with sales of €2,177 million.

The Group’s other major prescription drugs are Aprovel®, Eloxatin®, Aprida® and Multaq®.

Human Vaccines

Sanofi Pasteur, the vaccines division of sanofi-aventis, is a global leader with the world’s broadest range of human vaccines. The major vaccines that performed best in 2009 include Polio/Pertussis/Hib vaccines such as Pentacel® and Pentaxim®, along with influenza vaccines against seasonal and pandemic influenza, with 2009 sales of €968 million and €1,062 million respectively. During the same period, Sanofi Pasteur strengthened its leadership in emerging markets by acquiring Shantha Biotechnics in India and launching ShanChol® and SHAN5™ to meet needs in these markets.

Generics

Boosted by the consolidation of Zentiva, Laboratorios Kendrick and Medley, the Generics business in 2009 almost tripled to deliver sales of €1,012 million. The new European generics platform is now operational.

Consumer Healthcare

In February 2010, sanofi-aventis successfully completed its takeover bid for Chattem, and became the 5th largest player in the global market. In 2009, eight international brands: Doliprane®, Essentiale®, No-Spa®, Maalox®, Enterogermina®, Magne B6®, Dorflex®, and Lactacyd® grew by 22.1% while the total sales amounted to €1,430 million.

Animal Health

Merial, a sanofi-aventis subsidiary, is a leading producer of animal health products with Frontline® and Heartgard®. Merial posted net sales of 2,554 million US dollars in 2009.

1. World excepted United States, Canada, Western Europe (France, Germany, United Kingdom, Italy, Spain, Greece, Malta, Belgium, Luxemburg, Sweden, Portugal, Netherlands, Austria, Swiss, Ireland, Finland, Norway, Iceland, Denmark), Japan, Australia and New-Zealand.

2. Including Bristol-Myers Squibb sales.